Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12 Triple Negative Breast Neoplasms 6 Prostatic Neoplasms 6 Neoplasms 4 Neoplasm Metastasis 4 Ovarian Neoplasms 3 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Adenocarcinoma 1 Advanced Breast Cancer 1

Interventions

pembrolizumab 23 Gemcitabine 22 Nivolumab 15 atezolizumab 13 Cisplatin 13 avelumab 12 Carboplatin 11 Docetaxel 9 enfortumab vedotin 8 Paclitaxel 7 durvalumab 6 Magnetic Resonance Spectroscopy 6 Ipilimumab 6 pemigatinib 5 Specimen Handling 5 vinflunine 4 toripalimab 4 sacituzumab govitecan 4 cabozantinib 4 Taxes 4 Standard of Care 3 Pemetrexed 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 tislelizumab 2 sapanisertib 2 disitamab vedotin 2 cabazitaxel 2 Trastuzumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡